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HDR BRACHYTHERAPY OF CERVICAL CANCER- ASSESSMENT 
OF ACUTE TOXICITY-PROSPECTIVE STUDY 
BACKGROUND 
Cobalt-60 source HDR brachytherapy are now available for treatment with 
similar geometric and dosimetric properties as compared to iridium source but with 
longer half life. 
Aim 
To assess the acute gastrointestinal and genitourinary toxicities in patients 
treated with HDR brachytherapy in carcinoma cervix using cobalt-60 source. 
Secondary end points were to asses patient compliance and response assessment at the 
end of 3 months.  
Design-single arm prospective study. 
Methods and materials 
A total of 38 patients of FIGO stage IB2-IIIB carcinoma cervix were treated 
with EBRT of 50- 50. 4gy[180-200cgy/fraction],5days a week along with  cisplatin 
40mg/m2 weekly in telecobalt followed by intracavitory application 3# of HDR 
brachytherapywith 7 gy per #.toxicity assessment was done using RTOG toxicity 
criteria. 
Results 
In our study only grade 1[31.5%] and grade 2[10.52%] genitourinary and 
gastrointestinal symptoms [grade 1-28.94 % and grade 2-23.68%] were reported. 
Grade 3 GI toxicity was 2.63% though no grade 3 GU symptoms were seen. All 
patients were able to complete treatment in 7 weeks except for 1 patient who had 
grade iii gi toxicity complete. Response rate at the  end of 3 months was 92%( 
35)patients. 
Conclusion 
HDR brachytherapy with cobalt-60 has acceptable acute  toxicity profile along 
with cost effectiveness. 
